Go to ...

Nordens Ekonomi Norge

RSS Feed

18. november 2018

Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting


Euroinvestor.com A/S Euroinvestor.com A/S



- Characterization of emerging ICOS hi CD4 T cells from responding patients provides rationale for JTX-2011 combination therapies -



CAMBRIDGE, Mass., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a..

More Stories From

Do NOT follow this link or you will be banned from the site!
Read previous post:
Oljefondets infrastruktur-planer: Vind og sol i USA og Europa

Norges Bank sier at risikoen knyttet til investeringer i fornybar infrastruktur har blitt mindre. Oljefondet anbefaler særlig vind- og solkraft...

Close